BioSpace News Archive

Results of a long-term safety study of ARAKODA® (tafenoquine) in healthy volunteers have been published in the peer-reviewed journal Travel Medicine and Infectious Disease, according to 60 Degrees Pharmaceuticals, LLC (60P), a pharmaceutical company focused on developing new medicines for tropical diseases.

Procaps Group, a leading integrated international healthcare and pharmaceutical company, announced its financial results for the third quarter ended September 30, 2021.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of a territory exclusive distribution agreement in Taiwan.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will present an update on the Phase 2 IRENE trial in a poster at the 2021 San Antonio Breast Cancer Symposium (SABCS).

LevitasBio has announced the expansion of its product portfolio with the release of two new product lines that will enable researchers and laboratory personnel to better process and characterize human, animal and plant samples.

Oncopeptides AB will publish its report for the third quarter 2021 on November 24 . Investors, financial analysts, and media are invited to participate in a webcast with a Q&A session on the same day at 10:00 CET.

Pfizer Canada ULC and BioNTech SE today announced that Health Canada has authorized COMIRNATY, the companies’ COVID-19 vaccine for children 5 to under 12 years of age .

Jaguar Health, Inc. announced topline results of the third-party, investigator-initiated Phase 2 HALT-D trial evaluating crofelemer for the prevention of chemotherapy-induced diarrhea in HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab and a taxane.

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of ARV-471 will be presented in a spotlight poster-discussion session at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 7-10, 2021.

Rejuveron Life Sciences AG, a Zürich-based biotechnology company developing technologies for healthy aging, has announced the appointment of Bob Silverman as Chief Business Officer (CBO).